UCB announces initial clinical trial results involving patients taking certolizumab pegol for modera

(Thomson Reuters ONE) -

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 21.12.2009 - 07:00 Uhr
Sprache: Deutsch
News-ID 9879
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 513 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"UCB announces initial clinical trial results involving patients taking certolizumab pegol for modera"
steht unter der journalistisch-redaktionellen Verantwortung von

UCB (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

UCB presents latest research and clinical advancement across leading epilepsy po ...

- 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA® ...

UCB signs a new EUR 1.5 billion credit facility ...

Brussels, Belgium, December 15 2009 - 8:30 (CET). Regulated information. - UCB SA ("UCB" or the "Company") is pleased to announce the signing of its new EUR 1.5 billion revolving credit facility. The purpose of the facility is to ...

UCB completes the placement of 7-year bonds ...

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW The current news release consti ...

Alle Meldungen von UCB